|
Are you seeing a top tier LLMD? (I mean one who treats mostly by the ILADS guidelines or Burrascano's guidelines? You haven't told us how much doxy you're taking---- Burrascano's Guidelines mention 400 mg of doxy a day for an 'average' adult, with no extenuating circumstances. Anything under that amount is not treating.  (By normal standards) How long after your tick bite did you start antibiotics? If it wasn't IMMEDIATELY then you might be looking at months (sometimes years) of antibiotic treatment. Don't get upset with me for presenting the facts.  Read Burrascano's Guidelines. Read www.ilads. org Read www.lymeinfo.net And to touch on another subject: Your doctor said:
****he blew me off like: "Keep taking the Celebrex!"**** Ask him what he thinks of the Black Box warning issued for Celebrex om 2005. ***** Celebrex Gets Black Box Label August 2, 2005 Celebrex, the only COX-2 painkiller still on the market in the U.S., will carry the Food and Drug Administration�s toughest warning. The FDA has announced the drug will carry a so-called �black box� on its label, warning consumers of increased cardiovascular risks. Celebrex • Celebrex May Disrupt Heart Rhythm • Celebrex Gets Black Box Label • FDA Blasts Ads For Celebrex, Bextra • Can Pfizer Prevent Celebrex Ban? • Pfizer Finds Health Risk With Celebrex • Study Finds Celebrex Safer Than Vioxx • Celebrex Implicated in 14 Canadian Deaths --- Similar warnings have been mandated for ibuprofen and naproxen. Celebrex has been under close scrutiny since late last year, [2005] when Merck withdrew another COX-2 drug, Vioxx from the market. The FDA then asked Pfizer to take similar action with its COX-2 drug, Bextra. "We have worked closely with the FDA to ensure that Celebrex's label provides physicians and patients with the information they need to make the most appropriate and most informed treatment decisions," said Dr. Joseph Feczko, Pfizer's chief medical officer. The new warning on Celebrex's label will recommend the drug be prescribed at the lowest dose and shortest time possible. Doctors are also being cautioned that Celebrex should not be used following heart bypass surgery. While toughening the warning label, the FDA has approved the use of Celebrex for treatment of ankylosing spondylitis, a rare form of arthritis in the spine. It continues as an approved pain reliever for osteoarthritis and rheumatoid arthritis. Pfizer says the recommended dose for Celebrex is 200 mg daily for osteoarthritis and 200 mg to 400 mg daily for adult rheumatoid arthritis. For the management of the signs and symptoms of ankylosing spondylitis, the recommended dose of Celebrex is 200 mg daily in single or divided twice per day doses. In a way, the �black box� warning marks a victory for Pfizer�s strategy of keeping Celebrex on the market. The pharmaceutical company came under strong pressure late last year to withdraw the drug, as Merck had done with Vioxx. A Toronto newspaper published documents in which Canadian health officials blamed Celebrex for 14 deaths in Canada. But Merck took a major financial hit when it withdrew Vioxx and Pfizer seemed determined to avoid that fate. In December company executives strongly defended Celebrex, but pulled all radio and TV advertising for the drug. |
"For me MDJunction means I am no longer home alone all day. It means having friends who not only understand me but care for me as well. I am grateful to MDJunction for creating a world where I fit in just perfectly." (Yvonne802)
